American Society of Clinical Psychopharmacology (ASCP)

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Dr Goldberg and Dr Anita share previews of the upcoming ASCP Annual Meeting in Scottsdale, Arizona.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.

Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

An expert discusses the role of cognition in bipolar disorder and the potential of modafinil as a treatment for it at the 2024 ASCP Annual Meeting.

An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.

An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.

Attending the 2024 ASCP Annual Meeting? Be sure to catch these upcoming poster presentations.